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Abstract
Background: In Thailand, the proportion of Plasmodium vivax infection has become equal to Plasmodium
falciparum. Reports of a trend of gradual decline of in vitro sensitivity of P. vivax to chloroquine in some areas of
the country, together with accumulating evidences of chloroquine resistance P. vivax in other parts of the world,
emphasize the need for closely and continuously monitoring clinical efficacy in conjunction with in vitro sensitivity
of P. vivax isolates.
Methods: The study was conducted at Mae Tao clinic for migrant workers, Tak Province during March 2008 - August
2009. A total of 130 patients (17 Thais and 113 Burmeses; 64 males and 66 females) with mono-infection of P. vivax
malaria, aged between 15-60 years and weighing more than 40 kg, were included in the study. Patients received
treatment with chloroquine (2,000 mg chloroquine phosphate over three days) and the anti-relapse drug primaquine
(15 mg for 14 days). In vitro sensitivity of P. vivax isolates was evaluated by schizont maturation inhibition assay.
Results: All patients showed satisfactory response to treatment. The cure rate was virtually 100% within the follow-
up period of 42 days. Neither recurrence of P. vivax parasitaemia nor appearance of P. falciparum occurred during
the investigation period. In vitro data showed a stable sensitivity of chloroquine in this area since 2006. Geometric
mean and median (95% CI) values of IC50 for chloroquine were 100.1 and 134.7 (1.1-264.9) nM, respectively.
Conclusion: In vivo results suggest that the standard regimen of chloroquine was still very effective for the
treatment of blood infections with P. vivax in the Thai-Myanmar border area. In vitro sensitivity data however, raise
the possibility of potential advent of resistance in the future. Regular monitoring of the chloroquine sensitivity of P.
vivax is essential to facilitate the early recognition of treatment failures and to expedite the formulation of
appropriate changes to the drug policy.
Background
Plasmodium vivax is responsible for approximately 70 to
80 million cases of malaria worldwide annually, and is
the major cause of human malaria in parts of Pacific
region and Central and South America [1]. The disease
is rarely life-threatening, but morbidity from prolonged
illness and the possibility of relapses from a persistent
hepatic form (hypnozoite) are of major concern. Plasmo-
dium vivax can only infect reticulocytes, which limits
parasitaemia, usually to densities lower than 100,000/ml
blood. The relapses can occurs weeks, months or years
after initial exposure [2]. In Thailand, the proportion of
P. vivax infection has now been increasing and has
become equal to Plasmodium falciparum since 1998.
On the western border of Thailand, the incidence of
P. vivax has recently been reported as 20 per 1,000
population per year, similarly to that of P. falciparum
[3]. The blood schizontocide chloroquine and tissue
s c h i z o n t o c i d ep r i m a q u i n eh a v er e m a i n e dt h em a i n s t a y
chemotherapeutics for the treatment of P. vivax infec-
tion in Thailand for more than 60 years, with conserved
clinical efficacy of virtually 100% [3-5]. To date, there
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roquine-resistant P. vivax in Thailand. Nevertheless, a
trend of gradual decline of in vitro sensitivity to chlo-
roquine has been documented in some areas of
the country, particularly Thai-Myanmar border [6,7].
Furthermore, the accumulating reports of chloroquine
resistance P. vivax in other parts of the world during
the past three decades including Papua New Guinea
[8-11], Indonesia [12], Irian Jaya [13-16], Guyana South
America [17], Peru [18], Colombia [19], India [20],
Myanmar [21-23], Vietnam [24], Turkey [25], and Ethio-
pia [26] emphasize the need for closely and continuously
monitoring clinical efficacy in conjunction with in vitro
sensitivity of P. vivax isolates.
The objectives of the present study were to assess
in vivo efficacy of first-line regimen of chloroquine
given with primaquine, and in vitro susceptibility of
P. vivax isolates in areas along the Thai-Myanmar bor-
der to chloroquine and the new antifolate WR99120.
Methods
Study site
The study was conducted at Mae Tao clinic for migrant
workers, Tak Province during March 2008 - August
2009. Malaria is a serious imported medical problem in
this area with a low and stable disease transmission with
two seasonal peaks and forest-related during May-
August and November-January of each year. Anopheles
minimus and Anopheles dirus are the principal vectors.
P. falciparum and P. vivax are the two predominant
species with an incidence of 1:1, Plasmodium malariae
is occasionally found and Plasmodium ovale is rare [3].
All age groups are affected and nearly all the P. vivax
infections are symptomatic. The study was approved by
the Ethics Committee of the Ministry of Public Health
of Thailand.
Assessment of in vivo efficacy of chloroquine/primaquine
Patient recruitment and follow-up
A total of 130 patients (17 Thais and 113 Burmeses; 64
males and 66 females) with mono-infection with P. vivax
malaria, aged between 15-60 years (target population)
and weighing more than 40 kg were included in the
study. Inclusion criteria included a parasitaemia of 1,000-
100,000 parasites/μl blood, no signs of severe disease, no
anti-malarial treatment during the preceding four weeks,
no history of hepatic or kidney diseases. Written
informed consent for study participation was obtained
from all patients. All were admitted to the clinic during
the three-day course of chloroquine and were requested
to return for follow-up on days 7, 14, 21, 28, 35 and 42
after treatment initiation. Patients who developed fever
or signs/symptoms of malaria were asked to return to the
clinic for malaria blood examination.
On enrolment, each patient underwent a physical
examination. A symptom questionnaire was also com-
pleted. Parasite counts, body temperature and blood for
in vitro sensitivity test (1 ml blood collected into sodium
heparinized plastic tube).
Evaluation of clinical efficacy
The efficacy of chloroquine when given with primaquine
for the treatment of P. vivax malaria were assessed by
(i) the proportion of patients with cure (cure rate), i.e.,
those who showed clearance of parasitaemia in the per-
ipheral blood and absence of reappearance of parasitae-
mia within 42 days after treatment initiation, (ii) the
p a r a s i t ec l e a r a n c et i m e( P C T :t h et i m et a k e nf o rt h e
parasite count to fall below the level of microscopic
detection), and (iii) the fever clearance time (FCT: the
time taken for the temperature to return to normal, i.e.,
< 37.3°C and remain so for at least 24 hours).
Treatment
Patients received treatment with chloroquine given con-
currently with primaquine for eradication of hepatic stages
of P. vivax parasites. Chloroquine (Government Pharma-
ceutical Organization of Thailand, 250 mg chloroquine
phosphate per tablet) at a total dose of 2,000 mg given
over 3 days (500 mg, four times at 0 and 6-12 hours on
day-0, followed by 500 mg daily for two days) and prima-
quine (Government Pharmaceutical Organization of Thai-
land, 15 mg base given daily for 14 days starting from the
second day of chloroquine treatment and then once daily
until day-14). All drugs were administered with a glass of
250 ml drinking water under the supervision of medical
staff. Subjects were closely observed for at least 30 minutes
after each drug ingestion.
Patients whose parasitaemia was not cleared or those
who had a reappearance of P. vivax were to be treated
with the same regimen of chloroquine and primaquine
but the dose of primaquine was to be increased to
20 mg. Patients who developed parasitaemia with P. fal-
ciparum during the investigation period were to be
given a three-day treatment with oral artesunate (600
mg given in doses of 200 mg at 0, 6 and 24 hours) in
combination with mefloquine (1,250 mg given as 750
and 500 mg at 6-8 hours apart).
Laboratory investigations
Following the first dose of drug administration, parasite
counts (from finger-prick blood samples) were performed
in all patients at six hourly intervals until two consecutive
slides yielded negative results, and then during the fol-
low-up period until day 42. Blood films were stained with
Giemsa and examined by light microscope. Asexual
stages of P. vivax were counted against 1,000 erythrocytes
in thin blood films or against 200 white blood cells in
thick films. The examination was reported as negative
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examined without encountering a parasite. Parasite spe-
cies, morphology, and parasitaemia were assessed by
microscopic examination.
In vitro drug sensitivity assay
The schizont maturation assay was performed with
P. vivax field isolates collected from all patients using a
modified method of Russell and colleagues [27]. The
concentration of serum added to the culture medium
was increased from 10 to 30%. Plasmodium vivax field
isolates were tested for their sensitivities against chloro-
quine and WR99210 at the concentration ranges of
0-10,000 nM for chloroquine (chloroquine phosphate:
Liverpool School of Tropical Medicine, University of
Liverpool, UK) and 0-2,560 nM for WR99210 (Jacobus
Pharmaceutical Inc, Princeton, NJ, USA). The dose-
response curve was analysed by nonlinear regression
analysis using CalcuSyn™software (Biosoft™,C a m -
b r i d g e ,U K ) .T h er e s u l t sw e r e expressed as inhibitory
concentrations (IC) 10, 50 and 90, which are defined as
the concentrations of chloroquine or WR99120 produ-
cing 10, 50 and 90% inhibition of parasite development
as compared to the control. Quality control of the assay
was implemented by parallel determination of the IC50
of chloroquine against chloroquine-sensitive and chloro-
quine-resistant P. falciparum clones.
Results
Clinical efficacy
A total of 130 patients with P. vivax malaria were included
in the study and all had completed a 42 days follow-up
period. Demographic and clinical data are summarized in
Table 1. All patients showed good response following
treatment with median (95% CI) values for FCT and PCT
of 30 (18-36) and 24 (12-40) h, respectively. The cure rate
following treatment was 100%; there was no patient with
reappearance of parasitaemia during the 42 days follow-
up. None developed P. falciparum parasitaemia during the
investigation period.
In vitro sensitivity
In vitro sensitivity assay was performed in all of the 130
fresh P. vivax isolates collected; 32 (24.6%) with initial
parasitaemia between 2,120 and 64,360 parasites/μlw e r e
successfully assessed for in vitro sensitivity to chloro-
quine and WR99120. All isolates completely developed
to mature schizont within 20-40 h depending on domi-
nant stage prior to testing. Despite the variation of the
started parasite stages, abnormality in parasite morphol-
ogy was observed in all wells exposed to the test drugs.
Table 2 summarizes the IC10,I C 50 and IC90 values of
chloroquine and WR99120. Marked variation in IC50
values were observed for both chloroquine and
WR99120. Geometric mean and median (95% CI) values
of IC50 for chloroquine were 100.1 and 134.7 (1.1-264.9)
nM, respectively. Based on the cut-off IC50 of 100 nM
used to classify chloroquine resistance in P. falciparum
[28], 20 and 12 isolates, respectively exhibited IC50 values
of < and > 100 nM, respectively. Geometric mean and
median (95%CI) values of IC50 for WR99120 were 112.7
and 139.9 (0.2-523.0) nM, respectively.
Discussion
Difficulty in controlling vivax malaria is due to its biologi-
cal characteristics of repeated pre-erythrocytic develop-
ment due to relapse, with the maximum survival span of
hypnozoites of five years [3]. Radical treatment of the
infection, therefore, normally consists of a blood schizon-
tocidal course of chloroquine and a course of primaquine
for the elimination of the hypnozoites as antirelapse ther-
apy [29]. In most parts of the world, chloroquine remains
the first-line treatment for P. vivax infection in pregnant
and non-pregnant individuals [1]. In the present study, all
of the P. vivax patients enrolled in the study were satisfac-
torily treated with the standard regimen of chloroquine
with primaquine. All responded well to treatment, with no
reappearance of P. vivax parasitaemia (recrudescence or
relapse) or appearance of P. falciparum in peripheral
blood during the 42 days follow-up. There was no sign of
delayed parasitological and clinical response. The PCT (30
h) and FCT (24 h) were similar to our previous observa-
tion in 2006 [5] and a recent observation [30] in the same
area. Double infection with P. falciparum and P. vivax is
common in certain malaria-endemic areas of Thailand.
T h eo c c u r r e n c eo fs u b s e q u e n tP. falciparum following
treatment of P. vivax malaria has been reported to
be less frequent than that of P. vivax after treatment of
P. falciparum [31]. One possible explanation is the action
of primaquine on pre-erythrocytic and eryhtrocytic forms
of P. falciparum [32]. In addition, all patients stayed in
malaria non-endemic area during the follow up period,
which excluded the possibility of re-infection. So far, there
has been no reported case of chloroquine resistant
P. vivax in Thailand. Data from previous studies in differ-
ent endemic areas including Thai-Cambodian and Thai-
Myanmar borders during 1989 to 2011 [4-7,32] all
indicated full sensitivity of P. vivax to standard dose of
chloroquine. In a recent multicenter randomized, double-
blind, non-inferiority trial conducted in Cambodia, India,
Indonesia and Thailand (Mae Sot and Mae Ramat), a
42-day cure rate of chloroquine given with primaquine
was 100% [32]. Nevertheless, a recent clinical trial in
Ethiopia confirmed resistance of P. vivax to chloroquine
with a 28-day cure rate of 7.5% [33]. Reappearance of
P. vivax parasitaemia beyond day 28 which is suggested to
b ed u et ot r u er e l a p s ed u et op r i m a q u i n ef a i l u r e[ 2 9 ] ,
and the relapse rates within 1-6 months were reported to
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tropical areas [14,29]. Clinical effectiveness of primaquine
as an anti-relapse and patients’ compliance could not be
evaluated in this short follow-up investigation period.
The in vitro sensitivity data based on schizont matura-
tion inhibition test [27] demonstrated more or less the
stability of sensitivity of P. vivax isolates in this area of
Thailand to chloroquine [geometric mean IC50 of 100.1,
median (95%CI) of 134.7 (1.17-264.9) nM] since 2002
[27,34]. Sensitivity of P. vivax to chloroquine was shown
to be increased by about 2-fold (IC50: from 131 to
71 nM) in the presence of primaquine, which also pos-
sesses direct blood schizontocidal activity [5]. It was
n o t e dt h a tt h eI C 50 of chloroquine in P. vivax was about
2-fold of that of P. falciparum, but the variation is prob-
ably higher with P. vivax [35]. A previous study con-
d u c t e di nt h es a m ea r e af o rm o n i t o r i n go fin vitro
susceptibilities and molecular markers of resistance of
P. falicparum isolates to chloroquine, quinine, meflo-
quine and artesunate [35] showed the reversed sensitivity
of chloroquine after a period of about 40 years withdra-
wal from first-line treatment for falciparum malaria, with
median (95% CI) IC50 of chloroquine of 73 (10-164) nM.
One (4%), 19 (73%) and 6 (23%) isolates were classified as
chloroquine-sensitive, moderately resistant and highly
resistant P. falciparum, respectively. In other studies,
about 3-4 fold higher IC50 of chloroquine was observed
in P. vivax compared with P. falciparum [35,36]. This
may imply intrinsic characteristic (innate resistance) of
P. vivax in response to chloroquine. The in vitro cut-off
value defining clinically relevant chloroquine resistance
in P. vivax malaria has yet to be clearly defined. For
P. falciparum, cut-off IC50 of 100 nM was used to define
chloroquine resistance. Suwanarusk and colleagues [37]
defined the cut-off IC50 of 220 nM based on the 35
th per-
centile of the clinical failure rate of 65% observed in
Indonesian patients with P. vivax malaria. In the same
study [37], the IC50 of chloroquine in Thai isolates col-
lected from Mae Sot District, Thai-Myanmar border
(same area as the present study) was also found to be sig-
nificantly lower than that from Indonesian isolates (geo-
metric mean IC50 of 312 vs 46.8 nM). Eleven out of 81
Thai isolates (13.6%) exhibited IC50 of chloroquine over
220 nM. Based on this criteria, six out of 32 isolates
(18.8%) observed in the present study showed IC50 of
greater than 220 nM. The current in vivo and in vitro
results suggest that chloroquine is still an effective first-
line treatment for P. vivax in Thailand. Resistance level
may remain obviously below the threshold of detectabil-
ity by the in vivo method. It is noted that definitive
Table 1 Demographic and clinical data of patients with P. vivax infection included in the study
Number (%) or median (95%CI)
Patient characteristics:
Number included 130 (64 females, 66 males) (17 Thais, 113 Burmeses)
Age [years: median (95% CI)] 22 (15-55)
Admission parasitaemia [/μl: median (95% CI)] 4,898 (1,206-29,480)
Clinical outcome:
Number (%) completed 42 days follow-up 130 (100)
Number (%) cured by day 42 130 (100)
PCT [h: median (95% CI)] 30 (18-36)
FCT [h: median (95% CI)] 24 (12-42)
Data are presented as number (%) or median (95% CI).
PCT (parasite clearance time): The time taken for the parasite count to fall below the level of microscopic detection.
FCT (fever clearance time): the time taken for the temperature to return to normal, i.e., <37.3°C and remain so for at least 24 hours.
Table 2 Sensitivity of P. vivax to chloroquine and WR99120; data are presented as geometric mean and median (95%
CI) values of IC10,I C 50 and IC90 obtained from 32 isolates
Drugs Inhibitory Concentration (IC) Geometric mean (nM) Median (range) (nM)
Chloroquine IC10 3.3 4.2 (0.2-7.1)
IC50 100.1 134.7 (1.1-264.9)
IC90 2956.5 4134.9 (7.1-11535.0)
WR99210 IC10 4.9 5.7 (0.04-17.8)
IC50 112.7 139.9 (0.2-523.0)
IC90 2585.0 3406.9 (1.1-15356.0)
IC 10, 50 and 90: drug concentrations which produced 10, 50 and 90% inhibition of parasite development, respectively, as compared to the control (analysed by
nonlinear regression analysis using CalcuSyn™software).
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ate since chloroquine was given with primaquine, and the
fact that the study design did not include control arm
with chloroquine monotherapy due to ethical reason.
Regular monitoring of the chloroquine sensitivity of
P. vivax is essential as to facilitate the early recognition
of treatment failures and to expedite the formulation of
appropriate changes to the drug policy. Alternative treat-
ment options for P. vivax infection in case of chloroquine
resistance may include a three-day course of quinine
given concurrently with primaquine [5] or artemisinin
combination therapy [38].
Various in vitro assay systems with different endpoint
criteria have also been applied for monitoring of sensitiv-
ity of P. vivax isolates to anti-malarial drugs. Direct com-
parison of in vitro sensitivity data using different
methods should however, be interpreted with caution.
Since P. vivax infection is predominantly asynchronous,
the microscopic method based on inhibition of parasite’s
growth previously developed by our group [39] is consid-
ered the best-suited method for assessing sensitivity of
P. vivax to anti-malarial drugs [40]. The test method
based on schizont maturation inhibition used in the pre-
sent study, although may be less accurate, but the
method is extremely less labour-intensive, more applic-
able for field studies and does not require expensive or
dangerous reagents (monoclonal antibodies or radioiso-
topes). Unluckily, the success rate of in vitro sensitivity
test observed in the current study was relatively low
(24.6%), which is possibly due to variation in asynchroni-
city of parasite isolates in this area. Russel et al [41]
demonstrated the marked stage-specific activity of chlor-
oquine with variable growth rates. Isolates initially at the
trophozoite stage had significantly higher chloroquine
IC50 values than those initially at the ring stage. Synchro-
nous isolates which reached the target of 40% schizonts
in the control wells within 30 hours had significantly
higher geometic mean IC50 of chloroquine. In vitro sus-
ceptibility was found to be correlated with initial stage of
the parasite, with isolates predominantly at the tropho-
z o i t es t a g eh a v i n ga2 - f o l di n c r e a s ei nI C 50 values com-
pared to those of parasites predominantly at the ring
stage [41].
The spread of chloroquine resistance in P. falciparum
has led to the use of the antifolate combination sulpha-
doxine-pyrimethamine (SP) as the first-line drug for
malaria treatment in several countries including Thai-
land, where P. vivax and P. falciparum often co-exist and
occur at approximately equal frequencies [3]. In vitro
sensitivity of WR99210, a novel inhibitor of enzyme dihy-
drofolate reductase (DHFR) was assessed in our study in
view of previous reports showing its promise as a possible
treatment of P. vivax malaria. The drug shows activity
against the most pyrimethamine-resistant P. falciparum
strains and extremely effective inhibitor of the P. vivax
DHFR including mutations that confer high-level resis-
tance to pyrimethamine [42,43]. Median (95% CI) IC50 of
WR99120 in P. vivax isolates collected in the present
study was 139.9 (0.21-523.0) nM. The relatively poor in
vitro susceptibility of P. vivax to WR99120 observed was
similar to our previous observation in the same area [44],
could be explained by the slow action of this drug and/or
t h ei n n a t er e s i s t a n c ea sw e l la st h ep r e s e n c eo fp-amino-
benzoic acid and folate in the media used which acted as
competitive antagonists of antifolate activity [45].
The combination of new antifolates, like WR99210,
that are effective against SP-resistant parasites, with
appropriate partners, may also play an important role in
a rational drug treatment strategy.
Conclusions
Chloroquine is still sufficiently effective for blood schizon-
tocidal therapy in areas along the Thai-Myanmar border.
In vitro s e n s i t i v i t yd a t ah o w e v e rr a i s et h ep o s s i b i l i t yo f
potential advent of resistance in the future. Regular moni-
toring of chloroquine sensitivity of P. vivax is essential.
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